Dynavax Technologies (NASDAQ:DVAX) Rating Lowered to “Sell” at The Goldman Sachs Group
Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued on Tuesday, MarketBeat.com reports. They presently have a $12.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $15.00. The […]
Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued on Tuesday, MarketBeat.com reports. They presently have a $12.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $15.00. The […]
